Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
More News: AstraZeneca | Cardiology | Chronic Kidney Disease | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Heart | Urology & Nephrology